-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-01
TLPPF:OTC- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 16.475Change
-0.78 (-4.49)%Market Cap
USD 6.05BVolume
178.00Verdict
Verdict
Values as of: 2025-04-01
COMMON STOCK | Biotechnology |
Last Closing
USD 16.475Change
-0.78 (-4.49)%Market Cap
USD 6.05BVolume
178.00Verdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ARGNF | argenx SE |
N/A |
USD 42.38B |
UCBJY | UCB SA ADR |
+0.56 (+0.64%) |
USD 39.56B |
UCBJF | UCB SA |
N/A |
USD 39.40B |
GNMSF | Genmab A/S |
-7.06 (-3.69%) |
USD 14.30B |
WXXWY | WuXi Biologics (Cayman) Inc |
-0.17 (-2.48%) |
USD 12.58B |
WXIBF | WuXi Biologics |
N/A |
USD 12.52B |
AKESF | Akeso, Inc. |
+1.13 (+11.01%) |
USD 8.30B |
IVBIY | IVBIY |
N/A |
USD 7.97B |
SBHMY | Sino Biopharmaceutical Ltd ADR |
+0.92 (+9.81%) |
USD 7.81B |
SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 7.77B |
N/A
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 10.02% | 65% | D | 64% | D | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 10.02% | 65% | D | 65% | D | ||
Trailing 12 Months | |||||||
Capital Gain | 97.31% | 89% | A- | 92% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 97.31% | 89% | A- | 91% | A- | ||
Trailing 5 Years | |||||||
Capital Gain | 2,494.49% | 99% | N/A | 99% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 2,494.49% | 98% | N/A | 98% | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 99.04% | 74% | C | 84% | B | ||
Dividend Return | 99.04% | 74% | C | 84% | B | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 112.21% | 44% | F | 31% | F | ||
Risk Adjusted Return | 88.26% | 99% | N/A | 96% | N/A | ||
Market Capitalization | 6.05B | 96% | N/A | 87% | B+ |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.